Genomics, a genome analytics spin-out of Oxford University, has received £2m ($3m) after winning a competition run by Genomics England (GE), a company backed by the UK National Health Service (NHS).
The Small Business Research Initiative (SBRI) competition was seeking companies which are development technologies for the analysis and interpretation of genomic sequence data, and is part of GE’s 100,000 Genomes Project, which is looking to sequence 100,000 genomes from NHS patients by 2017.
It is the third such award Genomics has secured, and adds to a £10.3m series A round held in November last year. Investors in Genomics include IP Group, Invesco Perpetual, Woodfoord Investment Management, and Lansdowne Partners.
Peter Donnelly, co-founder of Genomics, said: “Genome sequence data can potentially transform healthcare, and the UK is playing a leading role in this process through the 100,000 Genomes Project. Our aim is to use our expertise to develop best-in-class tools for clinical genome interpretation and variant calling, and this award will accelerate our product deployment.”
